Philip Mease, MD
Rheumatologist, Director of Rheumatology Research, Clinical Professor
Director of Rheumatology Research
Swedish Medical Center/Providence-St Joseph Health
Swedish Medical Center/Providence St. Joseph Health
Seattle, WA, United States
Disclosure information not submitted.
In this session, attendees will learn about the Janus kinase (JAK) signaling pathway and why it is a pertinent therapeutic target for treating active ankylosing spondylitis (AS). Review of efficacy and safety data from a pivotal phase 3 randomized controlled trial of a prescription drug in patients with active AS will provide evidence for how JAK inhibition represents an innovative approach within the current AS treatment paradigm.
Developed & offered by Pfizer